IPP Bureau
FDA nod to Boehringer Ingelheim’s first-line therapy for HER2-mutant lung cancer
By IPP Bureau - February 28, 2026
Zongertinib is setting a new standard as the first targeted therapy for treatment naïve patients with HER2-mutant advanced non-small cell lung cancer with demonstrated efficacy
Combination therapy cuts death Risk in advanced prostate cancer: PEACE-3 trial
By IPP Bureau - February 28, 2026
PEACE-3 is a strong example of how academic cooperative research can help advance progress for complex diseases such as metastatic prostate cancer
Novartis’ remibrutinib bags positive CHMP opinion for chronic urticaria
By IPP Bureau - February 28, 2026
The oral therapy is aimed at adults with chronic spontaneous urticaria (CSU) who do not respond adequately to H1-antihistamines
Synthekine teams up with Merck to test breakthrough lung cancer combo
By IPP Bureau - February 28, 2026
The partnership will focus on the ongoing SYNERGY-101 randomized Phase 2 trial for first-line
Star Health & Allied Insurance rolls out 32 free primary care clinics across 9 states
By IPP Bureau - February 27, 2026
The initiative, funded entirely under the company’s CSR programme, is expected to reach over a million lives
Novo Nordisk slashes prices of Wegovy & Ozempic by up to 50%
By IPP Bureau - February 27, 2026
The company said the move applies to all doses and reflects its commitment to making its medicines more affordable for patients
Pfizer bags rull FDA nod for BRAFTOVI combination in aggressive colorectal cancer
By IPP Bureau - February 27, 2026
BRAFTOVI in combination with cetuximab and mFOLFOX6 had previously received accelerated approval in December 2024 based on objective response rate (ORR) results
Novo Nordisk & Vivtex team up to revolutionize oral hiologics
By IPP Bureau - February 27, 2026
Under the deal, Vivtex will license select oral drug-delivery technologies to Novo Nordisk
Merck Animal Health gets FDA nod for groundbreaking dog allergy drug NUMELVI
By IPP Bureau - February 27, 2026
Asahi Kasei secures global rights to novel Alchemedicine preclinical compounds
By IPP Bureau - February 26, 2026
Asahi Kasei Pharma receives worldwide exclusive rights for the research, development, manufacturing, and marketing of the active ingredients
Zydus to disrupt GLP-1 market with day-1 launch of innovative Semaglutide in India
By IPP Bureau - February 26, 2026
Zydus has developed an innovative Semaglutide Injection (15 mg/3 ml) in a prefilled cartridge administered using a patient-friendly reusable pen for which the company has exclusive rights
Genprex bags major patent wins in Japan & Europe for REQORSA cancer therapy
By IPP Bureau - February 26, 2026
The Japanese Patent Office has issued a favorable Appeal Decision granting a patent for the use of REQORSA Gene Therapy in combination with PD-L1 antibodies to treat cancer
Alembic Pharma secures USFDA approval for generic Lamotrigine orally disintegrating tablets
By IPP Bureau - February 26, 2026
The approved product is a generic version of the reference listed drug (RLD) Lamictal ODT by GlaxoSmithKline and is indicated for the treatment of epilepsy and bipolar disorder
Eugia Pharma receives USFDA Approval for Everolimus tablets
By IPP Bureau - February 26, 2026
Sanofi Consumer Healthcare India reports robust Q4 and FY’25 growth
By IPP Bureau - February 26, 2026
For the fourth quarter, revenue surged 47% year-on-year to Rs. 2,510 million, driven by a 23% rise in domestic sales and a 9.3x jump in export sales
